CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsLow earnings quality
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
448.39BKRW317.48M · vs all stocks (USD)
Trailing P/E
47.91xRevenue (TTM)
233.80BKRW165.54M · vs all stocks (USD)
Profit Margin
4.48%Beta
1.12xvs all stocks
52-Week Change
-35.22%vs all stocks
Market Capitalization
448.39BKRW317.48M · vs all stocks (USD)
Enterprise Value
503.92BKRW356.79M · vs all stocks (USD)
Trailing P/E
47.91xPEG Ratio
-0.3892xPrice to Sales (TTM)
1.93xPrice to Book (MRQ)
1.68xEnterprise to Revenue
2.15xEnterprise to EBITDA
18.67xGross Margin
39.26%Profit Margin
4.48%Operating Margin
-0.67%Return on Assets (TTM)
2.76%Return on Equity (TTM)
3.65%Revenue (TTM)
233.80BKRW165.54M · vs all stocks (USD)
Revenue per Share (TTM)
4.51KKRWUpdated Aug 19, 2026Quarterly Revenue Growth
-1.60%Gross Profit (TTM)
102.40BKRW72.50M · vs all stocks (USD)
EBITDA (TTM)
27.47BKRW19.45M · vs all stocks (USD)
Net Income (TTM)
10.10BKRW7.15M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-1.59%Operating Cash Flow (TTM)
23.44BKRW16.59M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
12.75BKRW9.02M · vs all stocks (USD)
5-Year Average Dividend Yield
1.15%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
752.64MKRWFY2025 · Dec 31, 2025Revenue
234.68BKRWFY2025 · Dec 31, 2025Cost of Goods Sold
132.01BKRWFY2025 · Dec 31, 2025Gross Profit
102.67BKRWFY2025 · Dec 31, 2025Operating Income
14.26BKRW10.09M · vs all stocks (USD)
Pre-tax Income
8.45BKRWFY2025 · Dec 31, 2025Income Tax Expense
62.48MKRWFY2025 · Dec 31, 2025Net Income
8.39BKRWFY2025 · Dec 31, 2025EBIT
11.14BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
25.41BKRWFY2025 · Dec 31, 2025Research & Development
10.44BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
28.54BKRWFY2025 · Dec 31, 2025Other Operating Expenses
-1.13BKRWFY2025 · Dec 31, 2025Non-operating Interest Income
767.26MKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
2.69BKRWFY2025 · Dec 31, 2025Net Income from Continuing Operations
8.39BKRWFY2025 · Dec 31, 2025Minority Interests (P&L)
435.95MKRWFY2025 · Dec 31, 2025Operating Cash Flow
3.02BKRWFY2025 · Dec 31, 2025Free Cash Flow
-455.21MKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
47.43BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
8.39BKRWFY2025 · Dec 31, 2025Other Non-cash Items
1.92BKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-1.12BKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-6.17BKRWFY2025 · Dec 31, 2025Capital Expenditures
-3.48BKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-513.09MKRWFY2025 · Dec 31, 2025Purchase of Investments
-121.68BKRWFY2025 · Dec 31, 2025Sale of Investments
110.96BKRWFY2025 · Dec 31, 2025Other Investing Activity
10.00KRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-14.19BKRWFY2025 · Dec 31, 2025Long-term Debt Issuance
11.88BKRWFY2025 · Dec 31, 2025Long-term Debt Payments
-6.75BKRWFY2025 · Dec 31, 2025Other Financing Charges
-10.00KRWFY2025 · Dec 31, 2025Net Financing Cash Flow
5.13BKRWFY2025 · Dec 31, 2025Shares Outstanding
51.71MSharesUpdated Aug 19, 2026Float Shares
39.41MSharesUpdated Aug 19, 2026% Held by Insiders
31.99%vs all stocks
% Held by Institutions
2.53%vs all stocks
Total Cash (MRQ)
76.61BKRW54.24M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.28KKRWUpdated Aug 19, 2026Total Debt (MRQ)
54.51BKRW38.59M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1865xCurrent Ratio (MRQ)
3.20xBook Value per Share (MRQ)
4.89KKRWUpdated Aug 19, 2026Total Assets
352.47BKRW249.56M · vs all stocks (USD)
Total Current Assets
206.74BKRWFY2025 · Dec 31, 2025Total Liabilities
81.74BKRWFY2025 · Dec 31, 2025Total Non-current Assets
145.73BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
14.83BKRWFY2025 · Dec 31, 2025Total Current Liabilities
66.91BKRWFY2025 · Dec 31, 2025Cash
47.43BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
47.43BKRWFY2025 · Dec 31, 2025Other Short-term Investments
24.07BKRWFY2025 · Dec 31, 2025Accounts Receivable
72.54BKRWFY2025 · Dec 31, 2025Inventory
58.48BKRWFY2025 · Dec 31, 2025Accounts Payable
7.10BKRWFY2025 · Dec 31, 2025Short-term Debt
44.36BKRWFY2025 · Dec 31, 2025Other Current Liabilities
2.77BKRWFY2025 · Dec 31, 2025Long-term Debt
11.50BKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
210.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
26.49BKRWFY2025 · Dec 31, 2025Retained Earnings
50.77BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
270.73BKRW191.69M · vs all stocks (USD)
Treasury Stock
8.73BKRWFY2025 · Dec 31, 202552-Week Low
6.31KKRWUpdated Aug 19, 202652-Week High
15.90KKRWUpdated Aug 19, 202652-Week Change
-35.22%vs all stocks
Beta
1.12xvs all stocks
50-Day MA
8.28KKRWUpdated Aug 19, 2026200-Day MA
11.42KKRWUpdated Aug 19, 2026Avg 10-Day Volume
68.93KSharesUpdated Aug 19, 2026Avg 30-Day Volume
72.00KSharesUpdated Aug 19, 2026Diluted EPS (TTM)
172.00KRWUpdated Aug 19, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.81
Altman Z-Score 4.74: safe zoneNotable
Altman Z-Score: 4.74
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Santhera Pharmaceuticals Holding AG
Tier 1ProductionApproval-Gated PipelineRuleRisk
Medy-Tox Inc.
Tier 1ProductionApproval-Gated PipelineRule
Dishman Carbogen Amcis Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Tellgen Corporation
Tier 1ProductionApproval-Gated PipelineRule
Animalcare Group Plc
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Shapuaisi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Allgens Medical Technology Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Golden Throat Holdings Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Eledon Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Guiyang Xintian Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Shandong Longda Meishi Co., Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Shanghai Geoharbour Construction Group Co. Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated